Determining how best to slow, stop or reverse Parkinson’s needs world-class collaborative science involving researchers, clinicians, the pharmaceutical industry and, most importantly, people who are living with Parkinson’s. This collaboration is at the heart of our research programme.
Our Research Strategy
Our goal is to cure Parkinson’s, with urgency, for people currently living with the condition. By “cure”, Cure Parkinson’s means disease-modifying therapy or therapies. Cure Parkinson’s does not fund research which is directed only to symptomatic relief. This means that the research we fund must aim to slow, stop or reverse underlying disease progression.Our Research Strategy
Apply for funding
We fund both preclinical and clinical research projects that have the potential to cure Parkinson’s. By “cure”, we mean a “disease-modifying therapy” that will slow, stop or reverse the underlying disease progression of Parkinson’s. In addition, we prioritise research which has the potential to translate into the clinic within five years.Apply for funding
Involving people with Parkinson’s in research
People with Parkinson’s are an essential part of our programme of research. It is important that drug candidates chosen for scientific reasons are also of relevance to people living with Parkinson’s now. For support with involving people living with Parkinson’s in a research study or trial, please get in touch.Contact us
Calling all early or mid career researchers! The 3P platform was created during lockdown as a way of allowing early career scientists the opportunity to present and discuss their research online to the scientific community, thereby continuing their professional development. Now labs are opening up, Cure Parkinson’s, Van Andel Institute and World Parkinson Coalition have decide to continue to host the interactive presentations focused on neurodegenerative research once each month.Find out more
Science of Parkinson’s Blog
Written by Dr Simon Stott (Deputy Director of Research, Cure Parkinson’s), this is Simon’s personal and independent perspective of what is happening in the world of Parkinson’s research, with regular updates detailing the science behind new discoveries, up to date clinical trial results, and introducing some of the people behind the research.Read more here
The Tom Isaacs Award
Each year the Tom Isaacs Award is presented to the researcher who has shown the greatest impact on the lives of people living with Parkinson’s and/or has involved people with Parkinson’s in a participatory way in their work.Find out more, and nominate
The AMRC Best Practice Guidance
Cure Parkinson’s is a member of the Association of Medical Research Charities (AMRC). We follow AMRC requirements and guidance for best practice in research. AMRC charities are obliged to follow rigorous research evaluation (peer review) processes to ensure that only research of the highest quality is supported.
Cure Parkinson’s has received a certificate of best practice in medical and health research peer review evaluated by the AMRC in their 2020 Peer Review Audit. The AMRC audits their member charities every 5 years to ensure that research funding applications are evaluated in accordance with their principles of peer review: accountability, balance, independent decision making, rotation of scientific advisers and impartiality.
The GP2 Program
The Global Parkinson’s Genetics Program (GP2) is an ambitious five-year project supported by the Aligning Science Across Parkinson’s (ASAP) initiative and executed in partnership with The Michael J. Fox Foundation for Parkinson’s Disease Research.
Specifically, GP2 are inviting supervisors based in Asia and Latin America to apply for funding for a trainee to pursue a higher research degree (PhD or equivalent) in the genetics of Parkinson’s disease (PD) or a related subject.